ZNTL vs. CYRX, LBPH, ARQT, ETNB, ELVN, PRTC, TNGX, AUPH, OCUL, and SAGE
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Cryoport (CYRX), Longboard Pharmaceuticals (LBPH), Arcutis Biotherapeutics (ARQT), 89bio (ETNB), Enliven Therapeutics (ELVN), PureTech Health (PRTC), Tango Therapeutics (TNGX), Aurinia Pharmaceuticals (AUPH), Ocular Therapeutix (OCUL), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical preparations" industry.
Cryoport (NASDAQ:CYRX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap transportation companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Zentalis Pharmaceuticals' net margin of -50.17%. Zentalis Pharmaceuticals' return on equity of -15.19% beat Cryoport's return on equity.
Cryoport currently has a consensus target price of $18.25, suggesting a potential upside of 36.91%. Zentalis Pharmaceuticals has a consensus target price of $37.14, suggesting a potential upside of 196.20%. Given Cryoport's stronger consensus rating and higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Cryoport.
92.9% of Cryoport shares are owned by institutional investors. 10.1% of Cryoport shares are owned by company insiders. Comparatively, 6.1% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cryoport has higher revenue and earnings than Zentalis Pharmaceuticals. Cryoport is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cryoport received 186 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 65.21% of users gave Cryoport an outperform vote while only 65.00% of users gave Zentalis Pharmaceuticals an outperform vote.
In the previous week, Cryoport had 3 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 32 mentions for Cryoport and 29 mentions for Zentalis Pharmaceuticals. Cryoport's average media sentiment score of 0.43 beat Zentalis Pharmaceuticals' score of 0.28 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Cryoport has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
Summary
Cryoport beats Zentalis Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
